All In Biotech

Drug Trial Radar · NCT05259839

A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma

A Dose Escalation and Expansion Study of Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Patients With Newly Diagnosed or Relapsed/Refractory Multiple Myeloma

Last checked: Nov 19, 2026Latest source record: Aug 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

283

Actual

Start

Oct 20, 2022

Primary completion

Sep 2033

Study completion Sep 2033

Sponsor

Lead sponsor
AbbVieAbbVie (ABBV)
Sponsor type
Industry
First posted
Mar 2, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Multiple myeloma (MM) is a plasma cell disease characterized by the growth of clonal plasma cells in the bone marrow. The purpose of this study is to assess the safety and toxicity of etentamig (ABBV-383) when co-administered with pomalidomide-dexamethasone (Pd), lenalidomide-dexamethasone (Rd), or daratumumab-dexamethasone (Dd), in adult participants with relapsed/refractory (R/R) multiple myeloma (MM). Adverse events and change in disease activity will be assessed. Etentamig is an investigational drug being developed for the treatment of R/R MM. Study doctors put the participants in groups called treatment arms. Etentamig co-administered with Pd, Rd, or Dd, will be explored. Each treatment arm receives a different treatment combination depending on stage of the study and eligibility. This study will include a dose escalation phase to determine the best dose of etentamig, followed by a dose expansion phase to confirm the dose. Approximately 320 adult participants with R/R MM will be enrolled in the study in approximately 48 sites worldwide. Participants will receive intravenous (IV) etentamig co-administered with oral/IV Pd, oral/IV Rd, or oral/IV/subcutaneous (SC) Dd in 28-day cycles. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at an approved institution (hospital or clinic). The effect of the treatment will be frequently checked by medical assessments, blood tests, questionnaires and side effects.

Conditions

  • Relapsed/Refractory Multiple Myeloma

Interventions

  • EtentamigDrug

    Intravenous (IV) Infusion

  • DexamethasoneDrug

    Oral; Tablet or IV Infusion

  • LenalidomideDrug

    Oral; Capsule

  • PomalidomideDrug

    Oral; Capsule

  • DaratumumabDrug

    Subcutaneous Injection (SC)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with Dose Limiting Toxicities (DLT) of EtentamigTime frame: Up to approximately 28 Days
  2. Number of Participants with Adverse Events (AEs)Time frame: Up to Approximately 3 Years

Locations

49 sites in 7 countries. Site status is shown where the registry gives one.

  • University of Arkansas for Medical Sciences /ID# 243096

    Little Rock, Arkansas

  • Sylvester Comprehensive Cancer Center /ID# 243673

    Miami, Florida

  • Moffitt Cancer Center /ID# 243437

    Tampa, Florida

  • University of Maryland, Baltimore /ID# 243679

    Baltimore, Maryland

  • Dana-Farber Cancer Institute /ID# 249529

    Boston, Massachusetts

  • University of Massachusetts - Worcester /ID# 243977

    Worcester, Massachusetts

  • University of Michigan Comprehensive Cancer Center Michigan Medicine /ID# 243438

    Ann Arbor, Michigan

  • The Valley Hospital /ID# 243829

    Paramus, New Jersey

  • Rutenberg Cancer Center /ID# 244647

    New York, New York

  • Memorial Sloan Kettering Cancer Center /ID# 244656

    New York, New York

  • Atrium Health Levine Cancer Institute /ID# 242851

    Charlotte, North Carolina

  • University of Texas - Southwestern Medical Center /ID# 243273

    Dallas, Texas

  • Huntsman Cancer Institute /ID# 242872

    Salt Lake City, Utah

  • University of Washington /ID# 243172

    Seattle, Washington

  • Froedtert Memorial Lutheran Hospital /ID# 242654

    Milwaukee, Wisconsin

  • St George Hospital - Kogarah /ID# 243740

    Kogarah, New South Wales, Australia

  • Calvary Mater Newcastle /ID# 243730

    Waratah, New South Wales, Australia

  • Monash Health - Monash Medical Centre - Clayton /ID# 244403

    Clayton, Victoria, Australia

  • St Vincent's Hospital Melbourne /ID# 256879

    Fitzroy Melbourne, Victoria, Australia

  • Peter MacCallum Cancer Ctr /ID# 256880

    Melbourne, Victoria, Australia

  • Epworth Healthcare /ID# 243734

    Richmond, Victoria, Australia

  • Fiona Stanley Hospital /ID# 244753

    Murdoch, Western Australia, Australia

  • Universitaetsklinikum Essen /ID# 242819

    Essen, Germany

  • Universitaetsklinikum Hamburg-Eppendorf /ID# 243141

    Hamburg, Germany

  • Universitaetsklinikum Tuebingen /ID# 242815

    Tübingen, Baden-Wurttemberg, Germany

  • Universitaetsklinikum Regensburg /ID# 242837

    Regensburg, Bavaria, Germany

  • Universitaetsklinikum Wuerzburg /ID# 242826

    Würzburg, Bavaria, Germany

  • IRCCS AOU di Bologna Policlinico Sant Orsola Malpighi /ID# 242581

    Bologna, Italy

  • Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico /ID# 244057

    Milan, Italy

  • Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST - IRCCS /ID# 242584

    Meldola, Forlì-Cesena, Italy

  • IRCCS Ospedale San Raffaele /ID# 242583

    Milan, Milano, Italy

  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS-Universita Cattolica /ID# 242582

    Rome, Roma, Italy

  • Nagoya City University Hospital /ID# 249094

    Nagoya, Aichi-ken, Japan

  • National Cancer Center Hospital East /ID# 245889

    Kashiwa-shi, Chiba, Japan

  • Hokkaido University Hospital /ID# 245966

    Sapporo, Hokkaido, Japan

  • Kanazawa University Hospital /ID# 246812

    Kanazawa, Ishikawa-ken, Japan

  • Okayama Medical Center /ID# 245882

    Okayama, Okayama-ken, Japan

  • Yamagata University Hospital /ID# 245888

    Yamagata, Yamagata, Japan

  • Szpital Wojewodzki w Opolu sp. z o.o. /ID# 243954

    Opole, Lower Silesian Voivodeship, Poland

  • Uniwersytecki Szpital Kliniczny We Wroclawiu /ID# 243246

    Wroclaw, Lower Silesian Voivodeship, Poland

Showing 40 of 49 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.